Randomized, Placebo-Controlled, Phase 2 Study Of Induction Chemotherapy With Cisplatin/Carboplatin, And Docetaxel With Or Without Erlotinib In Patients With Head And Neck Squamous Cell Carcinomas Amenable For Surgical Resection
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Feb 2018
At a glance
- Drugs Erlotinib (Primary) ; Carboplatin; Cisplatin; Docetaxel
- Indications Head and neck cancer
- Focus Therapeutic Use
- 29 Jan 2018 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 29 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 31 May 2016 Status changed from active, no longer recruiting to recruiting.